Barinthus Biotherapeutics (STU:2AB) Total Payout Ratio: 0.00 (As of Jul. 05, 2026)

What is Barinthus Biotherapeutics Total Payout Ratio?

Barinthus Biotherapeutics STU:2AB 14 Total Payout Ratio is 0.00 as of Jul. 05, 2026. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.94. The stock has 1 warning sign investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Barinthus Biotherapeutics's current Total Payout Ratio is 0.00.

Barinthus Biotherapeutics Total Payout Ratio Related Terms

Barinthus Biotherapeutics Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics Total Payout Ratio Chart

Barinthus Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Payout Ratio

Get a 7-Day Free Trial

2.01

-0.09

0.03

0.04

0.00

Barinthus Biotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Payout Ratio	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

STU:2AB vs VTGN, PSTV, PVCT: Total Payout Ratio Comparison

For the Biotechnology subindustry, Barinthus Biotherapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Barinthus Biotherapeutics Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's Total Payout Ratio falls into.

Save Embed

14GF Score

Barinthus Biotherapeutics PLC STU:2AB

Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Barinthus Biotherapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Barinthus Biotherapeutics's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-56.755
	=	0.00

Barinthus Biotherapeutics's Total Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-4.787
	=	0.00

Frequently Asked Questions Learn more about Total Payout Ratio →

What does a Total Payout Ratio of 0.00 mean?

Barinthus Biotherapeutics (STU:2AB) has a Total Payout Ratio of 0.00 as of Jul. 05, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Barinthus Biotherapeutics and its competitors.

Is Barinthus Biotherapeutics' Total Payout Ratio too high?

Barinthus Biotherapeutics' current Total Payout Ratio is 0.00. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.

How does Barinthus Biotherapeutics' Total Payout Ratio compare to VTGN and PSTV?

Barinthus Biotherapeutics' Total Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Payout Ratio for a Biotechnology company?

A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Payout Ratio mean?

A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Barinthus Biotherapeutics stock overvalued right now?

Barinthus Biotherapeutics (STU:2AB) has a current Total Payout Ratio of 0.00. The stock's GF Value™ is €0.94, compared to a current price of €0.52 — trading 44.7% below its estimated fair value. The current Total Payout Ratio is 0.00. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Payout Ratio calculated?

Total Payout Ratio is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Total Payout Ratio is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.52 is trading 44.7% below its estimated GF Value™ of €0.94.

Key valuation signals for STU:2AB:

Total Payout Ratio: 0.00
GF Value™: €0.94 vs. price of €0.52 (44.7% below fair value)
GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies VTGN PSTV PVCT KYNB TVGN GRDX DYAI NRSN SER LITS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges BRNS:USA

Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874

Website https://www.barinthusbio.com

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

14GF Score

Get the complete analysis for STU:2AB

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.52

Price

€0.94

GF Value

View STU:2AB Analysis

See Total Payout Ratio data for all stocks →